UBS Maintains Buy on AnaptysBio, Lowers Price Target to $60
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $90 to $60.
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $90 to $60.